Background Molnupiravir is an orally administered antiviral authorized for COVID-19
treatment in adults at high risk of progression to severe disease. Here, we report secondary …

Introduction The randomized, placebo-controlled, double-blind MOVe-OUT trial
demonstrated molnupiravir (800 mg every 12 h for 5 days) as safe and effective for …

Background New treatments are needed to reduce the risk of progression of coronavirus
disease 2019 (Covid-19). Molnupiravir is an oral, small-molecule antiviral prodrug that is …

Purpose Immunocompromised patients have a potentially increased risk for progression to
severe COVID-19 and prolonged replication of SARS-CoV-2. This post hoc analysis …

Background Safe and effective oral treatments are needed to improve clinical outcomes for
nonhospitalized patients with Covid-19. Molnupiravir is an orally administered, small …

Background The role of molnupiravir for coronavirus disease 2019 (COVID-19) treatment is
unclear. Methods We conducted a systematic review until 1 November 2022 searching for …

Background Molnupiravir was licensed for treating high-risk patients with COVID-19 based
on data from unvaccinated adults. AGILE CST-2 (NCT04746183) Phase II reports safety and …

Introduction Molnupiravir (MOV) is an oral antiviral for the treatment of individuals with mild-
to-moderate COVID-19 and at high risk of progression to severe disease. Our objective was …

Purpose Molnupiravir is an oral antiviral agent authorized for emergency use to treat mild to
moderate cases of coronavirus disease 2019 (COVID-19) in adults at high risk for …

Background: Molnupiravir is an oral prodrug with antiviral activity against severe acute
respiratory syndrome coronavirus-2 (SARS-CoV-2). Molnupiravir was initially developed for …